1- Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 1;33(1):118-27.


2- Humboldt Universität zu Berlin, Institut für Klinische Pharmakologie.

[Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's Wort].

Fortschr Neurol Psychiatr. 2004 Jun;72(6):330-43.


3- Department of Psychiatry and Psychotherapy, Medical University of Vienna, Währinger Gürtel 18-20, Austria.

Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.

Eur Neuropsychopharmacol. 2008 Nov;18(11):803-13.


4- Max Zeller Söhne Zeller AG, Seeblickstr. 4, CH-8590 Romanshorn, Switzerland.

Long-term effects of St. John's wort (Hypericum perforatum) treatment: a 1-year safety study in mild to moderate depression.

Phytomedicine. 2009 Apr;16(4):277-83.


5- Dept. of Internal Medicine, Institute of Complementary Medicine, University Hospital Zurich, Zurich, Switzerland.

A hypericum extract in the treatment of depressive symptoms in outpatients: an open study.

Forsch Komplementmed. 2010 Mar;17(1):7-14.


6- Department of Psychosomatic Medicine and Psychotherapy, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Germany.

St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial.

J Psychiatr Res. 2010 Sep;44(12):760-7.